Guidant Likely To Sing Over Duet's Success In 1999, Analysts Predict
This article was originally published in The Gray Sheet
Executive Summary
Heartfelt acceptance by interventional cardiologists of Guidant's Multi-Link Duet coronary stent in the final month of 1998 is expected to increase the company's share of the U.S. stent market to roughly 50%.
You may also be interested in...
Dr Reddy’s Knocked Back On Rituximab In US
Dr Reddy’s has received a complete response letter from the US FDA, knocking back its proposed rituximab biosimilar rival to Rituxan.
Sandoz And Samsung Celebrate Stelara Rival’s EU Approval
Sandoz and Samsung Bioepis have received final European Commission approval for their partnered Pyzchiva biosimilar rival to Stelara. But with European competition on ustekinumab due to kick off in just a matter of months, further applicants are also waiting in the wings.
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.